IMVARIA is a pioneering health tech company specializing in AI-driven digital biomarker solutions to empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease while reducing the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates a centralized, cloud-based AI Lab that transforms clinical decision-making into data science using automated, machine-learning algorithms across diverse clinical and laboratory datasets.

IMVARIA's flagship AI tools include Fibresolve and ScreenDx, which are FDA-authorized digital biomarker solutions aimed at providing non-invasive diagnostic assessments in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Fibresolve helps clinicians distinguish IPF from other ILDs, acting as an adjunct diagnostic tool prior to invasive testing. ScreenDx is designed to automatically assess for interstitial lung findings compatible with ILD to support referral pathways. The company is also developing Bronchosolve, an AI-powered investigational tool for assessing suspicious pulmonary nodules and advancing lung cancer diagnosis.

IMVARIA's mission is to redefine diagnostic and prognostic clinical assessments using AI biomarkers, enabling better decision-making for complex diseases like lung fibrosis, lung cancer, and other serious and rare diseases. Their technology supports clinicians, health systems, and biopharmaceutical partners in optimizing patient outcomes and advancing therapeutic development through innovative AI biomarker applications.

Based in Berkeley, California, IMVARIA offers its AI diagnostic services through a centralized digital lab model requiring no software integration. Contact can be made via [email protected] or phone at (650) 683-9800. More information is available on their website at www.imvaria.com.